Trial Outcomes & Findings for A Study to Evaluate SAGE-217 for Prevention of Relapse in Adult Participants With Major Depressive Disorder (NCT NCT04007367)
NCT ID: NCT04007367
Last Updated: 2023-11-29
Results Overview
Time to relapse was defined as days from the first dose of the study drug in the DB Phase to the day of relapse during the DB Phase. Participant was considered to have relapsed if: 2 consecutive HAM-D scores were ≥ 18 assessed 7 to 14 days apart, any worsening of depression requiring hospitalization, Investigator-determined risk of suicide, or any other clinically relevant event whether or not hospitalization was required. HAM-D is a scale used to rate depression in participants who were already diagnosed as depressed. The HAM-D total score comprised a sum of 17 individual item scores. Items scored in a range of 0 to 2 included: insomnia, somatic symptoms, genital symptoms, loss of weight, and insight. Items scored in a range of 0 to 4 included: agitation, depressed mood, feelings of guilt, suicide, work and activities, retardation, anxiety, hypochondriasis. The HAM-D total score could range from 0 (not depressed) to 52 (severely depressed). Higher scores indicated more depression.
TERMINATED
PHASE3
53 participants
Day 56 (Day 1 of DB Phase) up to Day 153 (i.e., up to 22 weeks)
2023-11-29
Participant Flow
Participants took part in this study at 28 investigative sites in the United States from 06 August 2019 to 06 January 2020.
The study was conducted in 2 parts: Open-Label (OL) and Double-Blind (DB) Phase. Participants received SAGE-217 during treatment period in OL Phase. Participants who exhibited a Hamilton Rating Scale for Depression response in OL Phase were to be randomized in a ratio of 1:1 to receive either SAGE-217 matching placebo or SAGE-217 oral capsule in DB Phase. However, the study was terminated by sponsor due to business decisions and only 2 participants entered the DB Phase and did not complete it.
Participant milestones
| Measure |
Open-Label Phase: SAGE-217
Participants self-administered SAGE-217, 30 milligrams (mg), oral capsule, once daily (QD) in the evening from Day 1 to Day 14.
|
Double-Blind Phase: Placebo
Following the OL Phase, participants who exhibited a Hamilton Rating Scale for Depression (HAM-D) response defined as a greater than or equal to (≥) 50% reduction from baseline in HAM-D total score were to be randomized to receive SAGE-217 matching placebo capsule, orally, QD, in the evening, in a total of five, 14-day treatment periods, each separated by a 6-week follow-up period during the 40-week DB Phase of the study. However, no participants were randomized to receive SAGE-217 matching placebo due to early study termination.
|
Double-Blind Phase: SAGE-217
Following the OL Phase, participants who exhibited a HAM-D response, defined as a ≥ 50% reduction from baseline in HAM-D total score to SAGE-217 were randomized to receive SAGE-217, 30 mg, oral capsule, QD, in the evening, up to study termination date (i.e., up to approximately 22 weeks) during the DB Phase of the study.
|
|---|---|---|---|
|
Open-Label Phase (8-Weeks)
STARTED
|
53
|
0
|
0
|
|
Open-Label Phase (8-Weeks)
COMPLETED
|
5
|
0
|
0
|
|
Open-Label Phase (8-Weeks)
NOT COMPLETED
|
48
|
0
|
0
|
|
Double-Blind Phase (14-Weeks)
STARTED
|
0
|
0
|
2
|
|
Double-Blind Phase (14-Weeks)
COMPLETED
|
0
|
0
|
0
|
|
Double-Blind Phase (14-Weeks)
NOT COMPLETED
|
0
|
0
|
2
|
Reasons for withdrawal
| Measure |
Open-Label Phase: SAGE-217
Participants self-administered SAGE-217, 30 milligrams (mg), oral capsule, once daily (QD) in the evening from Day 1 to Day 14.
|
Double-Blind Phase: Placebo
Following the OL Phase, participants who exhibited a Hamilton Rating Scale for Depression (HAM-D) response defined as a greater than or equal to (≥) 50% reduction from baseline in HAM-D total score were to be randomized to receive SAGE-217 matching placebo capsule, orally, QD, in the evening, in a total of five, 14-day treatment periods, each separated by a 6-week follow-up period during the 40-week DB Phase of the study. However, no participants were randomized to receive SAGE-217 matching placebo due to early study termination.
|
Double-Blind Phase: SAGE-217
Following the OL Phase, participants who exhibited a HAM-D response, defined as a ≥ 50% reduction from baseline in HAM-D total score to SAGE-217 were randomized to receive SAGE-217, 30 mg, oral capsule, QD, in the evening, up to study termination date (i.e., up to approximately 22 weeks) during the DB Phase of the study.
|
|---|---|---|---|
|
Open-Label Phase (8-Weeks)
Study Terminated by Sponsor
|
43
|
0
|
0
|
|
Open-Label Phase (8-Weeks)
Adverse Event
|
2
|
0
|
0
|
|
Open-Label Phase (8-Weeks)
Withdrawal by Participant
|
2
|
0
|
0
|
|
Open-Label Phase (8-Weeks)
Non-compliance
|
1
|
0
|
0
|
|
Double-Blind Phase (14-Weeks)
Withdrawal by Participant
|
0
|
0
|
2
|
Baseline Characteristics
A Study to Evaluate SAGE-217 for Prevention of Relapse in Adult Participants With Major Depressive Disorder
Baseline characteristics by cohort
| Measure |
Open-Label Phase: SAGE-217
n=53 Participants
Participants self-administered SAGE-217, 30 mg, oral capsule, QD in the evening from Day 1 to Day 14.
|
|---|---|
|
Age, Continuous
|
39.6 years
STANDARD_DEVIATION 12.16 • n=5 Participants
|
|
Sex: Female, Male
Female
|
37 Participants
n=5 Participants
|
|
Sex: Female, Male
Male
|
16 Participants
n=5 Participants
|
|
Ethnicity (NIH/OMB)
Hispanic or Latino
|
6 Participants
n=5 Participants
|
|
Ethnicity (NIH/OMB)
Not Hispanic or Latino
|
45 Participants
n=5 Participants
|
|
Ethnicity (NIH/OMB)
Unknown or Not Reported
|
2 Participants
n=5 Participants
|
|
Race (NIH/OMB)
American Indian or Alaska Native
|
0 Participants
n=5 Participants
|
|
Race (NIH/OMB)
Asian
|
3 Participants
n=5 Participants
|
|
Race (NIH/OMB)
Native Hawaiian or Other Pacific Islander
|
0 Participants
n=5 Participants
|
|
Race (NIH/OMB)
Black or African American
|
10 Participants
n=5 Participants
|
|
Race (NIH/OMB)
White
|
37 Participants
n=5 Participants
|
|
Race (NIH/OMB)
More than one race
|
3 Participants
n=5 Participants
|
|
Race (NIH/OMB)
Unknown or Not Reported
|
0 Participants
n=5 Participants
|
PRIMARY outcome
Timeframe: Day 56 (Day 1 of DB Phase) up to Day 153 (i.e., up to 22 weeks)Population: Due to early termination of the study by the sponsor, no data was collected, and no efficacy analysis was performed as planned, thus data is not available for this outcome measure.
Time to relapse was defined as days from the first dose of the study drug in the DB Phase to the day of relapse during the DB Phase. Participant was considered to have relapsed if: 2 consecutive HAM-D scores were ≥ 18 assessed 7 to 14 days apart, any worsening of depression requiring hospitalization, Investigator-determined risk of suicide, or any other clinically relevant event whether or not hospitalization was required. HAM-D is a scale used to rate depression in participants who were already diagnosed as depressed. The HAM-D total score comprised a sum of 17 individual item scores. Items scored in a range of 0 to 2 included: insomnia, somatic symptoms, genital symptoms, loss of weight, and insight. Items scored in a range of 0 to 4 included: agitation, depressed mood, feelings of guilt, suicide, work and activities, retardation, anxiety, hypochondriasis. The HAM-D total score could range from 0 (not depressed) to 52 (severely depressed). Higher scores indicated more depression.
Outcome measures
Outcome data not reported
SECONDARY outcome
Timeframe: Day 56 (Day 1 of DB Phase) up to Day 153 (i.e., up to 22 weeks)Population: Due to early termination of the study by the sponsor, no data was collected, and no efficacy analysis was performed as planned, thus data is not available for this outcome measure.
Participant was considered to have relapsed if: 2 consecutive HAM-D scores were ≥ 18 assessed 7 to 14 days apart, worsening of depression requiring hospitalization, Investigator-determined risk of suicide, or other clinically relevant events whether hospitalization was required. HAM-D scale was used to rate depression in participants who were diagnosed as depressed. Total score is a sum of 17 individual item scores. Items in a range of 0-2 included: insomnia (early, middle, late), somatic symptoms (gastrointestinal and general), genital symptoms, loss of weight, and insight. Items in a range of 0-4 included: agitation, depressed mood (sadness, hopeless, helpless, worthless), feelings of guilt, suicide, work and activities, retardation (slowness of thought and speech; impaired ability to concentrate; decreased motor activity), anxiety (psychic and somatic), hypochondriasis. Total score could range from 0 (not depressed)- 52 (severely depressed). Higher scores indicated more depression.
Outcome measures
Outcome data not reported
SECONDARY outcome
Timeframe: Day 56 (Baseline [Day 1] of DB Phase) up to Day 153 (i.e., up to 22 weeks)Population: Due to early termination of the study by the sponsor, no data was collected, and no efficacy analysis was performed as planned, thus data is not available for this outcome measure.
The 17-item HAM-D scale was used to rate the severity of depression in participants who were already diagnosed as depressed. The HAM-D total score comprised a sum of 17 individual item scores. Items scored in a range of 0 to 2 included: insomnia (early, middle, late), somatic symptoms (gastrointestinal and general), genital symptoms, loss of weight, and insight. Items scored in a range of 0 to 4 included: agitation, depressed mood (sadness, hopeless, helpless, worthless), feelings of guilt, suicide, work and activities, retardation (slowness of thought and speech; impaired ability to concentrate; decreased motor activity), anxiety (psychic and somatic), hypochondriasis. The HAM-D total score could range from 0 (not depressed) to 52 (severely depressed). Higher scores indicated more depression. A negative change from baseline indicated improvement.
Outcome measures
Outcome data not reported
SECONDARY outcome
Timeframe: Day 56 (Day 1 of DB Phase) up to Day 153 (i.e., up to 22 weeks)Population: Due to early termination of the study by the sponsor, no data was collected, and no efficacy analysis was performed as planned, thus data is not available for this outcome measure.
HAM-D response was defined as having a 50% or greater reduction from baseline in HAM-D total score. The HAM-D total score comprised a sum of 17 individual item scores. Items scored in a range of 0 to 2 included: insomnia (early, middle, late), somatic symptoms (gastrointestinal and general), genital symptoms, loss of weight, and insight. Items scored in a range of 0 to 4 included: agitation, depressed mood (sadness, hopeless, helpless, worthless), feelings of guilt, suicide, work and activities, retardation (slowness of thought and speech; impaired ability to concentrate; decreased motor activity), anxiety (psychic and somatic), hypochondriasis. The HAM-D total score could range from 0 (not depressed) to 52 (severely depressed). Higher scores indicated more depression.
Outcome measures
Outcome data not reported
SECONDARY outcome
Timeframe: Day 56 (Day 1 of DB Phase) up to Day 153 (i.e., up to 22 weeks)Population: Due to early termination of the study by the sponsor, no data was collected, and no efficacy analysis was performed as planned, thus data is not available for this outcome measure.
HAM-D remission was defined as having a HAM-D total score of ≤ 7. The HAM-D total score comprised a sum of 17 individual item scores. Items scored in a range of 0 to 2 included: insomnia (early, middle, late), somatic symptoms (gastrointestinal and general), genital symptoms, loss of weight, and insight. Items scored in a range of 0 to 4 included: agitation, depressed mood (sadness, hopeless, helpless, worthless), feelings of guilt, suicide, work and activities, retardation (slowness of thought and speech; impaired ability to concentrate; decreased motor activity), anxiety (psychic and somatic), hypochondriasis. The HAM-D total score could range from 0 (not depressed) to 52 (severely depressed). Higher scores indicated more depression.
Outcome measures
Outcome data not reported
SECONDARY outcome
Timeframe: Day 56 (Day 1 of DB Phase) up to Day 153 (i.e., up to 22 weeks)Population: Due to early termination of the study by the sponsor, no data was collected, and no efficacy analysis was performed as planned, thus data is not available for this outcome measure.
The CGI-I employs a 7-point Likert scale to measure the overall improvement in the participant's condition posttreatment. The Investigator rated the participant's total improvement whether or not it was due entirely to drug treatment. Response choices included: 1=very much improved, 2=much improved, 3=minimally improved, 4=no change, 5=minimally worse, 6=much worse, and 7=very much worse. The CGI-I is only rated at posttreatment assessments. By definition, all CGI-I assessments are evaluated against baseline conditions. Higher score indicated worse condition. CGI-I response was defined as having a CGI-I score of "very much improved" or "much improved."
Outcome measures
Outcome data not reported
SECONDARY outcome
Timeframe: Day 56 (Baseline [Day 1] of DB Phase) up to Day 153 (i.e., up to 22 weeks)Population: Due to early termination of the study by the sponsor, no data was collected, and no efficacy analysis was performed as planned, thus data is not available for this outcome measure.
The CGI-S uses a 7-point Likert scale to rate the severity of the participant's illness at the time of assessment, relative to the clinician's past experience with participants who had the same diagnosis. Considering total clinical experience, a participant was assessed on severity of mental illness at the time of rating as 1=normal, not at all ill; 2=borderline mentally ill; 3=mildly ill; 4=moderately ill; 5=markedly ill; 6=severely ill; and 7= among the most extremely ill participant. A higher score indicated extreme illness. A negative change from baseline indicated improvement (a higher absolute number indicating more illness).
Outcome measures
Outcome data not reported
SECONDARY outcome
Timeframe: Day 56 (Baseline [Day 1] of DB Phase) up to Day 153 (i.e, up to 22 weeks)Population: Due to early termination of the study by the sponsor, no data was collected, and no efficacy analysis was performed as planned, thus data is not available for this outcome measure.
The PHQ-9 is a participant-rated depressive symptom severity scale. To monitor severity over time participants in current treatment for depression, participants completed the questionnaires at baseline and at regular intervals thereafter. Scoring was based on responses to specific questions, as follows: 0=not at all; 1=several days; 2=more than half the days; and 3=nearly every day. The PHQ-9 total score was calculated as the sum of the 9 individual item scores and ranged from 0 to 27. The PHQ-9 total score was categorized as follows: 1 to 4=minimal depression, 5 to 9=mild depression, 10 to 14=moderate depression, 15 to 19=moderately severe depression; and 20 to 27=severe depression. Higher score indicated severe depression. A negative change from baseline indicated improvement.
Outcome measures
Outcome data not reported
SECONDARY outcome
Timeframe: Day 56 (Day 1 of DB Phase) up to Day 153 (i.e., up to 22 weeks)Population: Due to early termination of the study by the sponsor, no data was collected, and no efficacy analysis was performed as planned, thus data is not available for this outcome measure.
Time to relapse was defined as days from the first dose of the study drug in the DB Phase to the day of relapse during the DB Phase. Participant was considered to have relapsed if: 2 consecutive HAM-D scores were ≥18 assessed 7 to 14 days apart, any worsening of depression requiring hospitalization, Investigator-determined risk of suicide, or any other clinically relevant event whether or not hospitalization was required. HAM-D is a scale used to rate depression in participants who were already diagnosed as depressed. The HAM-D total score comprised a sum of 17 individual item scores. Items scored in a range of 0 to 2 included: insomnia, somatic symptoms, genital symptoms, loss of weight, and insight. Items scored in a range of 0 to 4 included: agitation, depressed mood, feelings of guilt, suicide, work and activities, retardation, anxiety, hypochondriasis. The HAM-D total score could range from 0 (not depressed) to 52 (severely depressed). Higher scores indicated more depression.
Outcome measures
Outcome data not reported
SECONDARY outcome
Timeframe: From the first dose of study drug up to the end of the study (i.e., up to approximately 22 weeks)Population: Safety Set included all participants who were administered the study drug. Data for this outcome measure was not collected for DB Phase: Placebo arm because none of the participants were enrolled into this group.
An adverse event (AE) was defined as any untoward medical occurrence in a participant or clinical investigation participant administered a pharmaceutical product and that does not necessarily have a causal relationship with this treatment. A TEAE was defined as an AE with onset after the start of study drug, or any worsening of a pre-existing medical condition/AE with onset after the start of study drug and throughout the study.
Outcome measures
| Measure |
Double-Blind Phase: Placebo
n=53 Participants
Following the OL Phase, participants who exhibited a HAM-D response defined as a ≥ 50% reduction from baseline in HAM-D total score were to be randomized to receive SAGE-217 matching placebo capsule, orally, QD, in the evening, in a total of five, 14-day treatment periods, each separated by a 6-week follow-up period during the 40-week DB Phase of the study. However, no participants were randomized to receive SAGE-217 matching placebo due to early study termination.
|
Double-Blind Phase: SAGE-217
Following the OL Phase, participants who exhibited a HAM-D response defined as a ≥ 50% reduction from baseline in HAM-D total score to SAGE-217 were randomized to receive SAGE-217, 30 mg, oral capsule, QD, in the evening, up to study termination date (i.e., up to approximately 22 weeks) during the DB Phase of the study.
|
Double-Blind Phase: SAGE-217
n=2 Participants
Following the OL Phase, participants who exhibited a HAM-D response defined as a ≥ 50% reduction from baseline in HAM-D total score to SAGE-217 were randomized to receive SAGE-217, 30 mg, oral capsule, QD, in the evening, up to study termination date (i.e., up to approximately 22 weeks) during the DB Phase of the study.
|
|---|---|---|---|
|
Number of Participants With Treatment-Emergent Adverse Events (TEAEs)
|
26 Participants
|
—
|
0 Participants
|
Adverse Events
Open-Label Phase: SAGE-217
Double-Blind Phase: Placebo
Double-Blind Phase: SAGE-217
Serious adverse events
Adverse event data not reported
Other adverse events
| Measure |
Open-Label Phase: SAGE-217
n=53 participants at risk
Participants self-administered SAGE-217, 30 mg, oral capsule, QD in the evening from Day 1 to Day 14.
|
Double-Blind Phase: Placebo
Following the OL Phase, participants who exhibited a HAM-D response defined as a ≥ 50% reduction from baseline in HAM-D total score were to be randomized to receive SAGE-217 matching placebo capsule, orally, QD, in the evening, in a total of five, 14-day treatment periods, each separated by a 6-week follow-up period during the 40-week DB Phase of the study. However, no participants were randomized to receive SAGE-217 matching placebo due to early study termination.
|
Double-Blind Phase: SAGE-217
n=2 participants at risk
Following the OL Phase, participants who exhibited a HAM-D response defined as a ≥ 50% reduction from baseline in HAM-D total score to SAGE-217 were randomized to receive SAGE-217, 30 mg, oral capsule, QD, in the evening, up to study termination date (i.e., up to approximately 22 weeks) during the DB Phase of the study.
|
|---|---|---|---|
|
Gastrointestinal disorders
Vomiting
|
5.7%
3/53 • From the first dose of study drug up to the end of the study (i.e., up to approximately 22 weeks)
Safety Set included all participants who were administered the study drug. Safety data for the placebo arm in the DB phase was not collected because none of the participants were enrolled in this group.
|
—
0/0 • From the first dose of study drug up to the end of the study (i.e., up to approximately 22 weeks)
Safety Set included all participants who were administered the study drug. Safety data for the placebo arm in the DB phase was not collected because none of the participants were enrolled in this group.
|
0.00%
0/2 • From the first dose of study drug up to the end of the study (i.e., up to approximately 22 weeks)
Safety Set included all participants who were administered the study drug. Safety data for the placebo arm in the DB phase was not collected because none of the participants were enrolled in this group.
|
|
Nervous system disorders
Dizziness
|
5.7%
3/53 • From the first dose of study drug up to the end of the study (i.e., up to approximately 22 weeks)
Safety Set included all participants who were administered the study drug. Safety data for the placebo arm in the DB phase was not collected because none of the participants were enrolled in this group.
|
—
0/0 • From the first dose of study drug up to the end of the study (i.e., up to approximately 22 weeks)
Safety Set included all participants who were administered the study drug. Safety data for the placebo arm in the DB phase was not collected because none of the participants were enrolled in this group.
|
0.00%
0/2 • From the first dose of study drug up to the end of the study (i.e., up to approximately 22 weeks)
Safety Set included all participants who were administered the study drug. Safety data for the placebo arm in the DB phase was not collected because none of the participants were enrolled in this group.
|
|
Nervous system disorders
Headache
|
9.4%
5/53 • From the first dose of study drug up to the end of the study (i.e., up to approximately 22 weeks)
Safety Set included all participants who were administered the study drug. Safety data for the placebo arm in the DB phase was not collected because none of the participants were enrolled in this group.
|
—
0/0 • From the first dose of study drug up to the end of the study (i.e., up to approximately 22 weeks)
Safety Set included all participants who were administered the study drug. Safety data for the placebo arm in the DB phase was not collected because none of the participants were enrolled in this group.
|
0.00%
0/2 • From the first dose of study drug up to the end of the study (i.e., up to approximately 22 weeks)
Safety Set included all participants who were administered the study drug. Safety data for the placebo arm in the DB phase was not collected because none of the participants were enrolled in this group.
|
|
Nervous system disorders
Sedation
|
7.5%
4/53 • From the first dose of study drug up to the end of the study (i.e., up to approximately 22 weeks)
Safety Set included all participants who were administered the study drug. Safety data for the placebo arm in the DB phase was not collected because none of the participants were enrolled in this group.
|
—
0/0 • From the first dose of study drug up to the end of the study (i.e., up to approximately 22 weeks)
Safety Set included all participants who were administered the study drug. Safety data for the placebo arm in the DB phase was not collected because none of the participants were enrolled in this group.
|
0.00%
0/2 • From the first dose of study drug up to the end of the study (i.e., up to approximately 22 weeks)
Safety Set included all participants who were administered the study drug. Safety data for the placebo arm in the DB phase was not collected because none of the participants were enrolled in this group.
|
|
Nervous system disorders
Somnolence
|
7.5%
4/53 • From the first dose of study drug up to the end of the study (i.e., up to approximately 22 weeks)
Safety Set included all participants who were administered the study drug. Safety data for the placebo arm in the DB phase was not collected because none of the participants were enrolled in this group.
|
—
0/0 • From the first dose of study drug up to the end of the study (i.e., up to approximately 22 weeks)
Safety Set included all participants who were administered the study drug. Safety data for the placebo arm in the DB phase was not collected because none of the participants were enrolled in this group.
|
0.00%
0/2 • From the first dose of study drug up to the end of the study (i.e., up to approximately 22 weeks)
Safety Set included all participants who were administered the study drug. Safety data for the placebo arm in the DB phase was not collected because none of the participants were enrolled in this group.
|
Additional Information
Results disclosure agreements
- Principal investigator is a sponsor employee Our agreement is subject to confidentiality but generally the PI can publish, for non-commercial purposes only, results and methods of the trial, but no other Sponsor Confidential Information. PI must give Sponsor no less than 60 days to review any manuscript for a proposed publication and must delay publication for up to an additional 90 days thereafter if Sponsor needs to file any patent application to protect any of Sponsor's intellectual property contained in the proposed publication.
- Publication restrictions are in place
Restriction type: OTHER